Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study

被引：0

作者：

Kumar, S. K. ^{[1
]}

Moreau, P. ^{[2
]}

Bahlis, N. ^{[3
]}

Facon, T. ^{[4
]}

Plesner, T. ^{[5
,6
]}

Orlowski, R. Z. ^{[7
]}

Basu, S. ^{[8
,9
]}

Nahi, H. ^{[10
]}

Hulin, C. ^{[11
]}

Quach, H. ^{[12
]}

Goldschmidt, H. ^{[13
,14
]}

O'Dwyer, M. ^{[15
]}

Perrot, A. ^{[16
]}

Venner, C. P. ^{[17
,18
]}

Weisel, K. ^{[19
]}

Raje, N. ^{[20
]}

Tiab, M. ^{[21
]}

Macro, M. ^{[22
]}

Frenzel, L. ^{[23
]}

Leleu, X. ^{[24
]}

Wang, G. ^{[25
]}

Krevvata, M. ^{[25
]}

Carson, R. ^{[25
]}

Borgsten, F. ^{[26
]}

Usmani, S. Z. ^{[27
]}

机构：

[1] Mayo Clin Rochester, Dept Hematol, Rochester, MN USA

[2] Univ Hosp Hotel Dieu, Hematol Dept, Nantes, France

[3] Univ Calgary, Arnie Charbonneau Canc Res Inst, Calgary, AB, Canada

[4] Univ Lille, CHU Lille, Serv Malad Sang, Lille, France

[5] Vejle Hosp, Vejle, Denmark

[6] Univ Southern Denmark, Vejle, Denmark

[7] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[8] Royal Wolverhampton NHS Trust, Wolverhampton, England

[9] Wolverhampton Univ, CRN West Midlands, NIHR, Wolverhampton, England

[10] Karolinska Inst, Karolinska Univ Hosp Huddinge, Div Hematol, Dept Med, Stockholm, Sweden

[11] Univ Hosp, Dept Hematol, Hop Haut Leveque, Pessac, France

[12] Univ Melbourne, St Vincents Hosp, Melbourne, Vic, Australia

[13] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany

[14] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[15] NUI, Dept Med Haematol, Galway, Ireland

[16] Univ Toulouse, CHU Toulouse, Serv Hematol, IUCT O,UPS, Toulouse, France

[17] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada

[18] BC Canc, Vancouver Ctr Grp, Vancouver, BC, Canada

[19] Univ Med Ctr Hamburg Eppendorf, Sect Pneumol, Dept Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany

[20] Massachusetts Gen Hosp, Canc Ctr, Ctr Multiple Myeloma, Boston, MA 02114 USA

[21] CHD Vendee, La Roche Sur Yon, France

[22] Ctr Hosp Univ CHU Caen, Caen, France

[23] Hop Necker Enfants Malad, Paris, France

[24] CHU Poitiers, Hop Miletrie, Poitiers, France

[25] Janssen Res & Dev LLC, Spring House, PA USA

[26] Janssen Res & Dev LLC, Raritan, NJ USA

[27] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P342

引用

页码：183 / 184

页数：2

共 50 条

[1] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
Kumar, Shaji K.
Moreau, Philippe
Bahlis, Nizar Jacques
Facon, Thierry
Plesner, Torben
Orlowski, Robert Z.
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Weisel, Katja
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Krevvata, Maria
Carson, Robin
Borgsten, Fredrik
Usmani, Saad
BLOOD, 2022, 140 : 10150 - 10153
[2] Updated Analysis of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): The Phase 3 Maia Study
Kumar, Shaji K.
Facon, Thierry
Usmani, Saad Z.
Plesner, Torben
Orlowski, Robert Z.
Touzeau, Cyrille
Basu, Supratik
Bahlis, Nizar J.
Goldschmidt, Hartmut
O'Dwyer, Michael E.
Venner, Christopher P.
Weisel, Katja
Hulin, Cyrille
Karlin, Lionel
Preis, Meir
Broyl, Annemiek
Renwick, William
Hansson, Markus
Krevvata, Maria
Wang, Jianping
Van Rampelbergh, Rian
Ukropec, Jon
Uhlar, Clarissa M.
Kobos, Rachel
Perrot, Aurore
BLOOD, 2020, 136
[3] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia
Bahlis, Nizar
Facon, Thierry
Usmani, Saad Z.
Kumar, Shaji K.
Plesner, Torben
Orlowski, Robert Z.
Touzeau, Cyrille
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael E.
Venner, Christopher P.
Weisel, Katja C.
Krevvata, Maria
Pei, Huiling
Wang, Jianping
Van Rampelbergh, Rian
Ukropec, Jon
Uhlar, Clarissa M.
Kobos, Rachel
Perrot, Aurore
BLOOD, 2019, 134
[4] Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)
Facon, Thierry
Kumar, Shaji K.
Plesner, Torben
Orlowski, Robert Z.
Moreau, Philippe
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Weisel, Katja
Mace, Joseph R.
Ahmadi, Tahamtan
Chiu, Christopher
Wang, Jianping
Van Rampelbergh, Rian
Uhlar, Clarissa M.
Kobos, Rachel
Qi, Ming
Usmani, Saad Z.
BLOOD, 2018, 132
[5] Phase 3 randomized study of Daratumumab plus lenalidomide and Dexamethasone (D-Rd) versus lenalidomide and Dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA)
Weisel, K.
Facon, T.
Kumar, S.
Plesner, T.
Orlowski, R. Z.
Moreau, P.
Bahlis, N.
Basu, S.
Nahi, H.
Hulin, C.
Quach, H.
Goldschmidt, H.
O'Dwyer, M.
Perrot, A.
Venner, C. P.
Mace, J. R.
Ahmadi, T.
Chiu, C.
Wang, J.
van Rampelbergh, R.
Uhlar, C. M.
Kobos, R.
Qi, M.
Usmani, S. Z.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 194 - 194
[6] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
Moreau, Philippe
Facon, Thierry
Usmani, Saad
Bahlis, Nizar Jacques
Raje, Noopur
Plesner, Torben
Orlowski, Robert Z.
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Weisel, Katja
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Krevvata, Maria
Carson, Robin
Borgsten, Fredrik
Kumar, Shaji K.
BLOOD, 2022, 140 : 7297 - 7300
[7] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 MAIA Study
Moreau, P.
Facon, T.
Usmani, S. Z.
Bahlis, N.
Raje, N.
Plesner, T.
Orlowski, R. Z.
Basu, S.
Nahi, H.
Hulin, C.
Quach, H.
Goldschmidt, H.
O'Dwyer, M.
Perrot, A.
Venner, C. P.
Weisel, K.
Tiab, M.
Macro, M.
Frenzel, L.
Leleu, X.
Wang, G.
Krevvata, M.
Carson, R.
Borgsten, F.
Kumar, S. K.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 238 - 238
[8] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 MAIA Study
Moreau, P.
Facon, T.
Usmani, S. Z.
Bahlis, N.
Raje, N.
Plesner, T.
Orlowski, R. Z.
Basu, S.
Nahi, H.
Hulin, C.
Quach, H.
Goldschmidt, H.
O'Dwyer, M.
Perrot, A.
Venner, C. P.
Weisel, K.
Tiab, M.
Macro, M.
Frenzel, L.
Leleu, X.
Pei, H.
Krevvata, M.
Carson, R.
Borgsten, F.
Kumar, S. K.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 316 - 317
[9] Overall survival (OS) results with Daratumumab (DARA), Lenalidomide and Dexamethasone (D-Rd) Vs Lenalidomide and Dexamethasone (Rd) in transplant-ineligible newly diagnosed multiple myeloma (TIE-NDMM): Phase 3 MAIA study
Weisel, K.
Facon, T.
Kumar, S.
Plesner, T.
Orlowski, R. Z.
Moreau, P.
Bahlis, N.
Basu, S.
Nahi, H.
Hulin, C.
Quach, H.
Goldschmidt, H.
O'Dwyer, M.
Perrot, A.
Venner, C. P.
Mace, J. R.
Raje, N.
Tiab, M.
Macro, M.
Frenzel, L.
Leleu, X.
Ahmadi, T.
Wang, J.
Rampelbergh, R., V
Uhlar, C. M.
Tromp, B.
Delioukina, M.
Vermeulen, J.
Usmani, S. Z.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 184 - 185
[10] Time to response, duration of response, and patient-reported outcomes (PROs) with daratumumab (DARA) plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of the phase 3 MAIA study.
Facon, Thierry
Kumar, Shaji
Plesner, Torben
Moreau, Philippe
Bahlis, Nizar J.
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Christopher
Venner, P.
Weisel, Katja
Mace, Joseph R.
Raje, Noopur S.
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Borgsten, Fredrik
Usmani, Saad Zafar
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →